Glenmark Pharma's US Unit to Launch Dextroamphetamine Saccharate Tablets, Bolstering CNS Portfolio

Glenmark Pharmaceuticals Ltd today announced that its U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA, is gearing up to launch Dextroamphetamine Saccharate Tablets in the US market. The launch signals a further strengthening of Glenmark's central nervous system (CNS) products portfolio and the company's continued commitment to offering high-quality, affordable generic medicines in the US.

 

Key Highlights:
 

Product Launch:

Glenmark Pharmaceuticals Inc., USA is soon going to make Dextroamphetamine Saccharate Tablets accessible to American patients. The drug is most commonly prescribed for the management of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy, which are very common CNS disorders.

 

Market Impact:

The launch of this product is opportune, considering the growing U.S. demand for ADHD treatments. Glenmark's entry is poised to increase patient access and provide a cost-effective remedy over branded and generic alternatives.

 

Regulatory Compliance:

The tablets are granted all relevant regulatory approvals, assuring that Glenmark complies with the high quality and effectiveness standards of the U.S. Food and Drug Administration (FDA).

 

Strategic Portfolio Growth:

The launch is consistent with Glenmark's vision of enhancing its footing in the U.S. generics business, with a specific emphasis on the CNS segment—a fundamental growth area of high potential.

 

Leadership Insights:

According to a spokesperson for Glenmark,

"This launch reflects our interest in building our U.S. portfolio with quality, essential CNS drugs. We are committed to addressing patient needs with dependable, accessible therapies."

 

Outlook:

With this addition, Glenmark Pharmaceuticals Inc., USA is well on its way to further enhancing its market share and solidifying its position as a market leader in affordable generics for complicated therapeutic areas.

 

Source: Company announcement, stock exchange filings, April 16, 2025.